Two death reports filed with the FDA have put the underground trade in "Reta" — bootleg retatrutide — under fresh scrutiny. The reports surfaced in national broadcast coverage on October 13, 2026, and while they do not establish causation, they represent the gravest safety signal yet connected to a black market that Eli Lilly has documented across more than 100 countries.
What Happened
Two deaths among people using bootleg retatrutide products were reported to the FDA, according to the October 13 reporting. Retatrutide — sold online under the shorthand "Reta" — is Lilly's investigational triple-agonist, simultaneously targeting GLP-1, GIP and glucagon receptors, and it remains unapproved in every market. Phase 3 readouts are still awaited, which means no pharmacy, clinic or website anywhere sells a legitimate version.
That makes every "Reta" vial on the grey market an unregulated product: unknown concentration, unknown sterility and, in the worst cases, an entirely different compound in the vial. FDA adverse-event reports are a signal rather than a verdict — they record that an exposure happened, not that the product caused the death. But safety officials treat clusters of serious reports around one unlicensed product as exactly the pattern that justifies enforcement crackdowns.
Who Is Affected
- Buyers of underground peptide sellers marketing "Reta" as a fast-track weight-loss drug
- Clinic and medical-spa customers sold compounded or copycat retatrutide outside any approved channel
- Legitimate researchers, whose work risks being tainted by association as grey-market incidents stack up
Timeline
- 2026: Retatrutide remains investigational; Phase 3 TRIUMPH data are still pending
- August 12, 2026: Lilly sues six sellers of illicit retatrutide, opening a formal enforcement campaign
- October 2026: Lilly expands the campaign with lawsuits against five more defendants
- October 13, 2026: National reporting describes two deaths reported to the FDA among users of bootleg "Reta"
What This Means for Researchers
For the research community the lesson is structural: a compound with no approved version has no legitimate retail supply, so anything sold as ready-to-use "Reta" is by definition uncontrolled material. Vials of unknown provenance cannot anchor serious bench work — identity, purity and endotoxin are all unverified. Our retatrutide research profile tracks what is actually documented about the compound while its clinical program matures.
How to Verify Your Peptides
Anyone holding material of uncertain origin can demand documentation before touching it:
- Learn what a legitimate testing workflow covers, from chain of custody to reporting
- Understand HPLC versus LC-MS testing and why both matter for identity and purity
- Check our primer on identity, purity and fill-weight verification
Safe Alternatives
- Browse our peptide research library for compounds with documented characterization
- Consult the vetted vendor directory — sellers screened for lab-tested products
- Read the retatrutide guide before drawing conclusions from headlines
Sources
- Regulatory announcements (FDA adverse-event reporting)
- Industry reports (Eli Lilly enforcement filings, 2026)